Gut microbiota disturbance during antibiotic therapy

Manuel Ferrer, Vitor AP Martins dos Santos, Stephan J Ott & Andrés Moya

To cite this article: Manuel Ferrer, Vitor AP Martins dos Santos, Stephan J Ott & Andrés Moya (2014) Gut microbiota disturbance during antibiotic therapy, Gut Microbes, 5:1, 64-70, DOI: 10.4161/gmic.27128

To link to this article: http://dx.doi.org/10.4161/gmic.27128

Published online: 13 Dec 2013.

Article views: 332

View related articles

View Crossmark data

Citing articles: 1 View citing articles
It is known that the gastrointestinal tract (GIT) microbiota responds to different antibiotics in different ways and that while some antibiotics do not induce disturbances of the community, others drastically influence the richness, diversity, and prevalence of bacterial taxa. However, the metabolic consequences thereof, independent of the degree of the community shifts, are not clearly understood. In a recent article, we used an integrative OMICS approach to provide new insights into the metabolic shifts caused by antibiotic disturbance. The study presented here further suggests that specific bacterial lineage blooms occurring at defined stages of antibiotic intervention are mostly associated with organisms that possess improved survival and colonization mechanisms, such as those of the Enterococcus, Blautia, Faecalibacterium, and Akkermansia genera. The study also provides an overview of the most variable metabolic functions affected as a consequence of a β-lactam antibiotic intervention. Thus, we observed that anabolic sugar metabolism, the production of acetyl donors and the synthesis and degradation of intestinal/colonic epithelium components were among the most variable functions during the intervention. We are aware that these results have been established with a single patient and will require further confirmation with a larger group of individuals and with other antibiotics. Future directions for exploration of the effects of antibiotic interventions are discussed.

Introduction

The human gastrointestinal tract (GIT) contains trillions of finely tuned bacteria, referred to as the GIT microbiota, which function as an organ with its own metabolism. A number of investigations have innovatively employed state-of-the-art technologies to explore, primarily, the bi-directional communication between the GIT and human health and, second, the way in which external factors such as nutrition and antibiotics modulate this loop. In this context, antibiotics could play a key role in the bi-directional communication between the gut and the host, and accordingly, this communication could also be modulated. There have been reports of microbial shifts associated...
with a number of antibiotics, including the following: (1) combined intravenous therapy with ampicillin, sulbactam, and cefazolin; (2) penicillin, vancomycin, and chlorotetracycline; (3) ciprofloxacin; (4) streptomycin; (5) ASP250 (chlorotetracycline, sulfanethazine and penicillin); (6) streptomycin; (7) amoxicillin and metronidazole; (8) metronidazole alone; and (9) vancomycin and imipenem, to cite just a few. Our group recently published omic results that demonstrated the potential of antibiotics to affect the energy metabolism of the GIT microbiota and its capacity to metabolize molecules known to be produced by the host (such as bile acids and sterols) or exclusively produced by bacteria (such as vitamins essential for neuronal development) during follow-up treatment. The treatment of a 68-y-old male with β-lactam therapy was used as a proof-of-concept; fecal samples were examined at days 0 (FS-0), 3 (FS-3), 6 (FS-6), 11 (FS-11), and 14 (FS-14) after the initiation of therapy and at 40 d after cessation of therapy. Here, we aimed to extend our knowledge regarding time-span-specific bacterial lineages and anabolic activity blooms occurring as a consequence of an antibiotic treatment through an in-depth examination of previously published data.

### Bacterial Blooms Occurring at Defined Stages of β-lactam Treatment

Our recent article showed that during an intervention, the administration of β-lactam intravenous therapy consisting of ampicillin, sulbactam, and cefazolin exerts changes both at the level of total bacterial populations at days 3 and 6 (in at least two replicates) but not in any other samples. This suggests that during β-lactam therapy, E. durans-like bacteria may survive in the intestinal environment and synthesize tyramine in the colon, drawing on this ability as a survival and colonization mechanism to enhance adhesion to the colonic mucosa. Additionally, a bloom of active Firmicutes sequences (~10.6%) occurred at day 6, while accounting for 1.4% at the beginning of the therapy and for ≤0.5% in other sampled populations, and no active members were found before or after the intervention. Cultivated members of this lineage have been shown to produce tyramine, a metabolite associated with tyrosine metabolism that has been found to be involved in the enhancement of bacterial adhesion. Although we did not measure the exact levels of tyramine in the sampled populations, an inspection of tyramine mass spectrometry (MS) adduct signatures ([M+H]+, [M+Na]+ and [M+K]+) in the HPLC-ESI-QTOF-MS chromatograms tentatively identified one or several such signatures in sampled populations at days 3 and 6 (in at least two replicates) but not in any other samples. Unfortunately, because there are no cultured representatives related to these sequences, the physiology of the represented bacteria remains unknown. A contrasting scenario was found for other Firmicutes members, such as those belonging to the genus Bifidobacterium, which were most active (up to ~27.8%) in the absence of antibiotic (FS-0 and FS-14) while contributing ≤1% in populations subjected to antibiotics (Table 1). Finally, bacteria assigned to the Faecalibacterium and Ruminococcus genera were most

### Table 1. Active bacterial composition based on 16S rRNA analyses in the follow-up study

<table>
<thead>
<tr>
<th>Sample</th>
<th>Bacteroidetes</th>
<th>Firmicutes</th>
<th>Actinobacteria</th>
<th>Proteobacteria</th>
<th>Verrucomicrobia</th>
</tr>
</thead>
<tbody>
<tr>
<td>FS-0</td>
<td>23.15%</td>
<td>1.37%</td>
<td>0.53%</td>
<td>0.03%</td>
<td>0.00%</td>
</tr>
<tr>
<td>FS-3</td>
<td>24.74%</td>
<td>0.51%</td>
<td>0.63%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>FS-6</td>
<td>10.83%</td>
<td>0.52%</td>
<td>0.62%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>FS-11</td>
<td>36.12%</td>
<td>0.52%</td>
<td>0.40%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>FS-14</td>
<td>74.24%</td>
<td>0.51%</td>
<td>3.13%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>FS-40</td>
<td>20.98%</td>
<td>0.57%</td>
<td>4.38%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
</tbody>
</table>

Samples FS-0, FS-3, FS-6, FS-11, and FS-14 correspond to the materials collected on days 0, 3, 6, 11, and 14 of the antibiotic treatment, respectively. The FS-40 sample corresponds to the materials collected 40 days after cessation of the antibiotic treatment. Only bacteria with abundance level higher than 1% were included.
active after the end of the antibiotic treatment (Table 1). Thus, they were from 8.3- to 192-fold more active (in terms of the total number of sequences assigned to these genera) at the end of the therapy than before. This indicates that Clostridiales have an increased fitness relative to all other Firmicutes identified in the community when the intervention ended. It is noteworthy that the significant decline in the diversity of Blautia and Faecalibacterium lineages has been suggested to play a role in improved intestinal permeability because these bacteria influence mucin synthesis and composition.41-43 This may be a reason for the active Enterococcus bloom that uses tyramine as a strategy to colonize a “modified” colonic mucosa.39,40

A division-wide bloom of naturally antibiotic-resistant Bacteroidetes44 was also observed. While species of Alistipes become most active at day 6 (~6.6%), the maximum bloom of active Parabacteroides species (P. merdae and P. distasonis) occurred at day 11 (~17.4%), and that of active Bacteroides species (B. fragilis, B. dorei, B. uniformis and B. ovatus) occurred at day 14 (~74.2%) (Table 1). This time-delay effect has also been observed after gentamicin and ceftriaxone treatment in mice.44 Indeed, bacteria belonging to the Bacteroides lineage have been shown to acquire and metabolize a wide range of sugars, using a carbohydrate acquisition strategy based on outer membrane proteins that confers a competitive growth advantage.46,47 This suggests that the bloom of these active bacteria may have metabolic consequences at the level of carbohydrate metabolism. In agreement with this, among all sampled populations, protein extracts from the fecal sample at day 14 have been recently shown to be the most active in terms of sugar hydrolysis.48

As observed for the Firmicutes, a bloom of bacteria affiliated with unclassified active Bacteroidetes sequences occurred at days 3 (~11.3%) and 6 (~13.4%) while accounting for ≤4.7% in other sampled populations (Table 1); unfortunately, because there are no cultured representatives related to these sequences, the physiology of the represented bacteria remains unknown. Finally, it is noteworthy that in contrast to Firmicutes members, no significant bloom of any active Bacteroidetes occurred after the end of the antibiotic therapy. This indicates that the Bacteroidetes have an increased fitness only when the end of the treatment is approaching (days 6 to 14), most likely because these microorganisms are able to develop resistance to several antimicrobial drugs due to the production of endogenous β-lactamases.44

Within Actinobacteria inhabitants, the Bifidobacterium spp. became most active at day 3 (4.4%) while accounting for 1.4% before the intervention and for ≤0.7% in other sampled populations (Table 1). Additionally, bacteria affiliated with unclassified active Actinobacteria sequences (~2.2%) were strongly affected by the antibiotic, becoming strongly depleted during and after the intervention (~0.4%); a similar situation was observed for Betaproteobacteria assigned to the Gemmiger genus, which accounted for 4.4% before the treatment and less than 0.7% in other sampled populations (Table 1). Finally, we observed a significant activation of mucin-degrading commensal bacteria assigned to the Akkermansia genus, which are members of the Verrucomicrobia, at day 6 (~6.6%) and, to a much lesser extent, at day 11 (~2.0%) (Table 1). In other sampled populations, no sequences assigned to active Akkermansia were detected, and this genus only accounted for 0.5% of the total
active community before the intervention. The activation of this bacterial group at days 6 and 11 agrees with our experimental evidence that demonstrated that mucin degradation increased at these time points.48 These data also agree with the results of previous investigations that suggest a link between mucin degradation, gut inflammation, and the abundance of Akkermansia muciniphila.49

Time-Span Prevalence of Active Proteins and Associated Functions

Our shotgun community protein expression data30 allowed us to characterize the time-span representation of active proteins and the functions assigned to them (Kyoto Encyclopedia of Genes and Genomes annotations, TGRFAM annotations, and Enzyme Commission numbers). Analysis of TGRFAM, KEGG, and EC proteome annotations identified 138 out of 394, 107 out of 304 and 58 out of 192 identifiers, respectively, that were differentially represented within the sampled populations; this constitutes approximately 30–35% of the total of the identifiers assigned to variable functions within the sampled populations. We ranked the variable functions according to the number of active and/or expressed proteins assigned to them; thus, we give more importance to those functions that have higher coverage. Table 2 shows the top-15 ranking of the most variable KEGG categories within the sampled populations. Nine of these categories correspond to pathways required for the production of acetyl phosphate and acetyl-CoA (Fig. 2). These are essential molecules involved in many cellular functions, including energy production, cellular respiration, gene expression, and proteolysis.50 Additionally, reactions possibly involved in pyrimidine metabolism (EC 2.1.3.2) and propanediol (propanal dehydrogenase) metabolism (Fig. 2) were also variable in their presence or absence during and after the intervention. This suggests that the antibiotic-induced changes at the level of the active microbiota structure may have implications for the production of a limited set of key metabolic compounds involved in major cellular functions and whose abundance and expression levels vary over the duration of the therapy.

Conclusions

Research efforts to elucidate the impact of antibiotic treatment on the GIT microbiota have mainly focused on monitoring community shifts and analyzing metagenomic data reflecting differences that result from shifts in community composition. However, little is known about the functional consequences

![Graphical representation of the pathways involved in the metabolism of acetyl phosphate and acetyl-CoA that have been shown to differ in their prevalence (based on the presence or absence of enzymes assigned to the pathways) in all six sampled communities. The enzymes (with EC numbers) implicated in each particular reaction are specifically indicated. Discontinuous lines indicate multiple reactions involved in the transformation.](image-url)
of these shifts on the cross-talk between gut microbial metabolism and host response. Moreover, the role played by specific bacterial blooms in GIT composition and metabolism at defined stages remains to be established. In this study, we contribute to the understanding of the complex and dynamic interplay among antibiotics and the microbiota and mucosa of the GIT. We found that with the administration of β-lactam antibiotics, the thickness of the mucus layer in the gut of rats was increased approximately 2-fold.37 Further investigations are required to ascertain which antibiotics produce the least collateral effects in the gastrointestinal tract while maintaining efficacy in the treatment of bacterial infections. Indeed, future studies should investigate (1) how to reduce the antibiotic-induced blooms of bacteria that are likely involved in the degradation of intestinal and/or colonic epithelium components during antibiotic intervention, and (2) the way antibiotics influence essential functional groups, such as biochemical activities and metabolites, that are required for maintaining human health. In both cases, it will be necessary to create a comprehensive data repository for microbial diversity (total and active) and functional data using computational and experimental strategies. Such strategies will help to generate knowledge and hypotheses that may lay a foundation for subsequent, systematic research and ultimately enable the design of personalized interventions.

Disclosure of Potential Conflicts of Interest
No potential conflict of interest was disclosed.

Acknowledgments
The whole consortium was funded by the Spanish Ministry of Economy and Competitiveness and the Federal Ministry of Education and Research (BMBF) within the ERA NET PathoGenoMics2 program.

Table 2. Ranking of variable KEGG identifiers with high protein/enzyme coverage using metaproteomic data

<table>
<thead>
<tr>
<th>KEGGID</th>
<th>Name</th>
<th>Rank</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>K00975</td>
<td>Glucose-1-phosphate dehydrogenase [EC 1.1.1.47]</td>
<td>1</td>
<td>40</td>
</tr>
<tr>
<td>K02357</td>
<td>Elongation factor Ts</td>
<td>2</td>
<td>34</td>
</tr>
<tr>
<td>K00659</td>
<td>Aspartate carboxyltransferase catalytic subunit [EC 2.1.3.2]</td>
<td>3</td>
<td>30</td>
</tr>
<tr>
<td>K00615</td>
<td>Transketolase [EC 2.2.1.1]</td>
<td>4</td>
<td>29</td>
</tr>
<tr>
<td>K00625</td>
<td>Phosphatase [EC 3.1.3.1]</td>
<td>5</td>
<td>28</td>
</tr>
<tr>
<td>K00626</td>
<td>Acetyl-CoA C-acetyltransferase [EC 2.3.1.1]</td>
<td>6</td>
<td>26</td>
</tr>
<tr>
<td>K00927</td>
<td>Phosphoglycerate kinase [EC 2.7.2.3]</td>
<td>7</td>
<td>25</td>
</tr>
<tr>
<td>K10172</td>
<td>O2-evolving decarboxylase beta subunit [EC 4.1.1.3]</td>
<td>8</td>
<td>24</td>
</tr>
<tr>
<td>K00209</td>
<td>Polar aminoo-acid transport system permease protein</td>
<td>9</td>
<td>23</td>
</tr>
<tr>
<td>K02117</td>
<td>V-ATPase transporting ATPase subunit A [EC 3.6.3.14]</td>
<td>10</td>
<td>22</td>
</tr>
<tr>
<td>K03798</td>
<td>Cell division protein FtsH [EC 3.4.24.-]</td>
<td>11</td>
<td>21</td>
</tr>
<tr>
<td>K03885</td>
<td>NADH dehydrogenase [EC 1.6.99.3]</td>
<td>12</td>
<td>20</td>
</tr>
<tr>
<td>K10549</td>
<td>D-Allose transport system substrate-binding protein</td>
<td>13</td>
<td>19</td>
</tr>
<tr>
<td>K10670</td>
<td>Glycine reductase [EC 1.2.1.42]</td>
<td>14</td>
<td>18</td>
</tr>
<tr>
<td>K13122</td>
<td>Propionaldehyde dehydrogenase [EC 1.2.1.3]</td>
<td>15</td>
<td>17</td>
</tr>
</tbody>
</table>

Score refers to the number of proteins/enzymes assigned to a particular KEGG ID as found in the metaproteomic dataset in all sampled populations.

Gut Microbes Volume 5 Issue 1

©2014 Landes Bioscience. Do not distribute.
References


